Pharmacogenomics and Pharmacokinetics of Efavirenz 400 or 600 mg in 184 Treatment-Naive HIV-Infected Patients in China

References

• OARAC . Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. (2019). www.aidsinfo.nih.gov/guidelines
   Google Scholar
• European AIDS Clinical Society . EACS guidelines (version 9.1). (2018). http://www.eacsociety.org/files/2018_guidelines-9.1-english.pdf
   Google Scholar
• Li X , BrownTT , HoKSet al. Recent trends and effectiveness of antiretroviral regimens among men who have sex with men living with HIV in the United States: the Multicenter AIDS Cohort Study (MACS) 2008–2017. Open Forum Infect. Dis.6(9), z333 (2019).
   Web of Science ®Google Scholar
• Chen R , ChenJ , TangQet al. Use of comedications and potential drug–drug interactions in people living with HIV in China. J. Infect. Chemother.26(7), 722–728 (2020).
   PubMed Web of Science ®Google Scholar
• Amariles P , GalindoJ , Mueses-MarinHFet al. Effectiveness and safety of generic version of lamivudine/tenofovir and efavirenz in treatment naive HIV-infected patients: a nonrandomized, open-label, Phase IV study in Cali-Colombia, 2012–2014. Rev. Chilena Infectol.36(1), 32–40 (2019).
   PubMed Web of Science ®Google Scholar
• Harrington BJ , DiPreteBL , JumbeANet al. Safety and efficacy of Option B+ ART in Malawi: few severe maternal toxicity events or infant HIV infections among pregnant women initiating tenofovir/lamivudine/efavirenz. Trop. Med. Int. Health24(10), 1221–1228 (2019).
   PubMed Web of Science ®Google Scholar
• Cassetti I , MadrugaJV , SuleimanJMet al. The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naive HIV-1-infected patients. HIV Clin. Trials8(3), 164–172 (2007).
   PubMed Web of Science ®Google Scholar
• Kenedi CA , GoforthHW. A systematic review of the psychiatric side-effects of efavirenz. AIDS Behav.15(8), 1803–1818 (2011).
   PubMed Web of Science ®Google Scholar
• Sim J , HillA. Is pricing of dolutegravir equitable? A comparative analysis of price and country income level in 52 countries. J. Virus Erad.4(4), 230–237 (2018).
   PubMed Web of Science ®Google Scholar
• Vitoria M , HillA , FordNet al. The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries: what are the issues? AIDS 32(12), 1551–1561 (2018).
   PubMed Web of Science ®Google Scholar
• Carey D , PulsR , AminJet al. Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study. Lancet Infect. Dis.15(7), 793–802 (2015).
   PubMed Web of Science ®Google Scholar
• Carey D . Efavirenz 400 mg daily remains non-inferior to 600 mg: 96 week data from the double-blind, placebo-controlled ENCORE1 study. J. Int. AIDS Soc.17(3 Suppl. 4), 19523 (2014).
   PubMedGoogle Scholar
• Kouanfack C , Mpoudi-EtameM , OmgbaBPet al. Dolutegravir-based or low-dose efavirenz-based regimen for the treatment of HIV-1. N. Engl. J. Med.381(9), 816–826 (2019).
   PubMed Web of Science ®Google Scholar
• ENCORE1 Study Group . Efficacy of 400mg efavirenz versus standard 600mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial. Lancet383(9927), 1474–1482 (2014).
   PubMed Web of Science ®Google Scholar
• WHO . Policy Brief: Update of Recommendations on First- and Second-Line Antiretroviral Regimens. (WHO/CDS/HIV/19.15). Licence: CC BY-NC-SA 3.0 IGO.2019. (2019). https://apps.who.int/iris/bitstream/handle/10665/325892/WHO-CDS-HIV-19.15-eng.pdf?sequence=1&isAllowed=y
   Google Scholar
• Ayuso P , NearyM , ChiongJet al. Meta-analysis of the effect of CYP2B6, CYP2A6, UGT2B7 and CAR polymorphisms on efavirenz plasma concentrations.J. Antimicrob. Chemother.74(11), 3281–3290 (2019).
   PubMed Web of Science ®Google Scholar
• Cusato J , TomaselloC , SimieleMet al. Efavirenz pharmacogenetics in a cohort of Italian patients. Int. J. Antimicrob. Agents47(2), 117–123 (2016).
   PubMed Web of Science ®Google Scholar
• Dickinson L , AminJ , ElseLet al. Pharmacokinetic and pharmacodynamic comparison of once-daily efavirenz (400 mg vs. 600 mg) in treatment-naive HIV-infected patients: results of the ENCORE1 study. Clin. Pharmacol. Ther.98(4), 406–416 (2015).
   PubMed Web of Science ®Google Scholar
• Meng X , YinK , WangJet al. Effect of CYP2B6 gene polymorphisms on efavirenz plasma concentrations in chinese patients with HIV infection. PLoS ONE10(6), e130583 (2015).
   PubMed Web of Science ®Google Scholar
• Sinxadi PZ , LegerPD , McIlleronHMet al. Pharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa. Br. J. Clin. Pharmacol.80(1), 146–156 (2015).
   PubMed Web of Science ®Google Scholar
• Boffito M , LamordeM , WatkinsMet al. Antiretroviral dose optimization: the future of efavirenz 400 mg dosing. Curr. Opin. HIV AIDS12(4), 339–342 (2017).
   PubMed Web of Science ®Google Scholar
• Cerrone M , WangX , NearyMet al. Pharmacokinetics of efavirenz 400 mg once daily coadministered with isoniazid and rifampicin in human immunodeficiency virus-infected individuals. Clin. Infect. Dis.68(3), 446–452 (2019).
   PubMed Web of Science ®Google Scholar
• Lamorde M , WangX , NearyMet al. Pharmacokinetics, pharmacodynamics and pharmacogenetics of efavirenz 400 mg once daily during pregnancy and post-partum. Clin. Infect. Dis.67(5), 785–790 (2018).
   PubMed Web of Science ®Google Scholar
• Chen J , ChenR , ShenYet al. Efficacy and safety of lower dose tenofovir disoproxil fumarate and efavirenz versus standard dose in HIV-infected, antiretroviral-naive adults: a multicentre, randomized, noninferiority trial. Emerg. Microbes Infect.9(1), 843–850 (2020).
   PubMed Web of Science ®Google Scholar
• Barrett JC , FryB , MallerJet al. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics21(2), 263–265 (2005).
   PubMed Web of Science ®Google Scholar
• Manosuthi W , SukasemC , LueangniyomkulAet al. Impact of pharmacogenetic markers of CYP2B6, clinical factors and drug–drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients. Antimicrob. Agents Chemother.57(2), 1019–1024 (2013).
   PubMed Web of Science ®Google Scholar
• Lloret-Linares C , RahmounY , LopesAet al. Effect of body weight and composition on efavirenz, atazanavir or darunavir concentration. Therapie73(3), 185–191 (2018).
   PubMed Web of Science ®Google Scholar
• Gutierrez-Valencia A , VicianaP , PalaciosRet al. Stepped-dose versus full-dose efavirenz for HIV infection and neuropsychiatric adverse events: a randomized trial. Ann. Intern. Med.151(3), 149–156 (2009).
   PubMed Web of Science ®Google Scholar
• Haas DW , RibaudoHJ , KimRBet al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS18(18), 2391–2400 (2004).
   PubMed Web of Science ®Google Scholar
• Swart M , EvansJ , SkeltonMet al. An expanded analysis of pharmacogenetics determinants of efavirenz response that includes 3′-UTR single nucleotide polymorphisms among Black South African HIV/AIDS patients. Front Genet.6, 356 (2015).
   PubMed Web of Science ®Google Scholar
• Habtewold A , AmogneW , MakonnenEet al. Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients. J. Antimicrob. Chemother.66(10), 2350–2361 (2011).
   PubMed Web of Science ®Google Scholar
• Gallien S , JournotV , LoriotMAet al. Cytochrome 2B6 polymorphism and efavirenz-induced central nervous system symptoms: a substudy of the ANRS ALIZE trial. HIV Med.18(8), 537–545 (2017).
   PubMed Web of Science ®Google Scholar
• Soeria-Atmadja S , OsterbergE , GustafssonLLet al. Genetic variants in CYP2B6 and CYP2A6 explain interindividual variation in efavirenz plasma concentrations of HIV-infected children with diverse ethnic origin. PLoS ONE12(9), e181316 (2017).
   Web of Science ®Google Scholar
• Grilo NM , CorreiaMJ , SequeiraCet al. Efavirenz biotransformation as an up-stream event of mood changes in HIV-infected patients. Toxicol. Lett.260, 28–35 (2016).
   PubMed Web of Science ®Google Scholar
• Svard J , SpiersJP , MulcahyFet al. Nuclear receptor-mediated induction of CYP450 by antiretrovirals: functional consequences of NR1I2 (PXR) polymorphisms and differential prevalence in whites and sub-Saharan Africans. J. Acquir. Immune Defic. Syndr.55(5), 536–549 (2010).
   PubMed Web of Science ®Google Scholar
• Sukasem C , ManosuthiW , KoomdeeNet al. Low level of efavirenz in HIV-1-infected Thai adults is associated with the CYP2B6 polymorphism. Infection42(3), 469–474 (2014).
   PubMed Web of Science ®Google Scholar
• Sanchez MA , CabreraFS , CruzGRet al. Impact of pharmacogenetics on CNS side effects related to efavirenz. Pharmacogenomics14(10), 1167–1178 (2013).
   PubMed Web of Science ®Google Scholar
• de Almeida TB , de AzevedoM , PintoJet al. Drug metabolism and transport gene polymorphisms and efavirenz adverse effects in Brazilian HIV-positive individuals. J. Antimicrob. Chemother.73(9), 2460–2467 (2018).
   PubMed Web of Science ®Google Scholar
• Cortes CP , SiccardiM , ChaikanAet al. Correlates of efavirenz exposure in Chilean patients affected with human immunodeficiency virus reveals a novel association with a polymorphism in the constitutive androstane receptor. Ther. Drug Monit.35(1), 78–83 (2013).
   PubMed Web of Science ®Google Scholar
• Holzinger ER , GradyB , RitchieMDet al. Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants. Pharmacogenet. Genomics22(12), 858–867 (2012).
   PubMed Web of Science ®Google Scholar
• Hui KH , LeeSS , LamTN. Dose optimization of efavirenz based on individual CYP2B6 polymorphisms in Chinese patients positive for HIV. CPT Pharmacometrics Syst. Pharmacol.5(4), 182–191 (2016).
   PubMedGoogle Scholar
• Zubiaur P , Saiz-RodriguezM , OchoaDet al. Influence of CYP2B6 activity score on the pharmacokinetics and safety of single dose efavirenz in healthy volunteers. Pharmacogenomics J.20(2), 235–245 (2020).
   PubMed Web of Science ®Google Scholar
• Desta Z , GammalRS , GongLet al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2B6 and efavirenz-containing antiretroviral therapy. Clin. Pharmacol. Ther.106(4), 726–733 (2019).
   PubMed Web of Science ®Google Scholar
• Ward BA , GorskiJC , JonesDRet al. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J. Pharmacol. Exp. Ther.306(1), 287–300 (2003).
   PubMed Web of Science ®Google Scholar
• Dickinson L , AminJ , ElseLet al. Comprehensive pharmacokinetic, pharmacodynamic and pharmacogenetic evaluation of once-daily efavirenz 400 and 600 mg in treatment-naive HIV-infected patients at 96 weeks: results of the ENCORE1 study. Clin. Pharmacokinet.55(7), 861–873 (2016).
   PubMed Web of Science ®Google Scholar
• Apostolova N , FunesHA , Blas-GarciaAet al. Efavirenz and the CNS: what we already know and questions that need to be answered. J. Antimicrob. Chemother.70(10), 2693–2708 (2015).
   PubMed Web of Science ®Google Scholar
• Mollan KR , TierneyC , HellwegeJNet al. Race/ethnicity and the pharmacogenetics of reported suicidality with efavirenz among clinical trials participants. J. Infect. Dis.216(5), 554–564 (2017).
   PubMed Web of Science ®Google Scholar
• Vujkovic M , BellamySL , ZuppaAFet al. Polymorphisms in cytochrome P450 are associated with extensive efavirenz pharmacokinetics and CNS toxicities in an HIV cohort in Botswana. Pharmacogenomics J.18(5), 678–688 (2018).
   PubMed Web of Science ®Google Scholar
• Varshney E , SahaN , TandonMet al. Prevalence of poor and rapid metabolizers of drugs metabolized by CYP2B6 in North Indian population residing in Indian national capital territory. Springerplus1, 34 (2012).
   PubMedGoogle Scholar
• Ribaudo HJ , LiuH , SchwabMet al. Effect of CYP2B6, ABCB1 and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study. J. Infect. Dis.202(5), 717–722 (2010).
   PubMed Web of Science ®Google Scholar
• Sukasem C , CresseyTR , PrapaithongPet al. Pharmacogenetic markers of CYP2B6 associated with efavirenz plasma concentrations in HIV-1 infected Thai adults. Br. J. Clin. Pharmacol.74(6), 1005–1012 (2012).
   PubMed Web of Science ®Google Scholar
• Poeta J , LindenR , AntunesMVet al. Plasma concentrations of efavirenz are associated with body weight in HIV-positive individuals. J. Antimicrob. Chemother.6(11), 2601–2604 (2011).
   Google Scholar
• Guo F , ChengX , HsiehEet al. Prospective plasma efavirenz concentration assessment in Chinese HIV-infected adults enrolled in a large multicentre study. HIV Med.19(7), 440–451 (2018).
   Web of Science ®Google Scholar
• Pereira SA , BrancoT , CaixasUet al. Intra-individual variability in efavirenz plasma concentrations supports therapeutic drug monitoring based on quarterly sampling in the first year of therapy. Ther. Drug Monit.30(1), 60–66 (2008).
   PubMed Web of Science ®Google Scholar